RT Journal Article
T1 Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy.
A1 Julià, Antonio
A1 López-Lasanta, María
A1 Blanco, Francisco
A1 Gómez, Antonio
A1 Haro, Isabel
A1 Mas, Antonio Juan
A1 Erra, Alba
A1 Vivar, Ma Luz García
A1 Monfort, Jordi
A1 Sánchez-Fernández, Simón
A1 González, Isidoro
A1 Alperi, Mercedes
A1 Castellanos-Moreira, Raúl
A1 Fernández-Nebro, Antonio
A1 Díaz-Torné, César
A1 Palau, Núria
A1 Lastra, Raquel
A1 Lladós, Jordi
A1 Sanmartí, Raimon
A1 Marsal, Sara
K1 Anti-TNF therapy
K1 Autoantibodies
K1 Rheumatoid arthritis
K1 Treatment response
AB Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50-60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction between these four antibodies in relation to the response to anti-TNF therapy. For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA.
YR 2021
FD 2021-04-21
LK http://hdl.handle.net/10668/17615
UL http://hdl.handle.net/10668/17615
LA en
DS RISalud
RD Apr 5, 2025